Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

被引：0
|
作者：
Makoto Araie
Kazuhisa Sugiyama
Kenji Aso
Koji Kanemoto
Kalyani Kothapalli
Casey Kopczynski
Michelle Senchyna
David A. Hollander
机构：
[1] Kanto Central Hospital of the Mutual Aid Association of Public School Teachers,Department of Ophthalmology
[2] Kanazawa University Graduate School of Medical Science,undefined
[3] Aerie Pharmaceuticals Ireland Ltd. (Japan Branch),undefined
[4] Statistics and Data Corporation,undefined
[5] Aerie Pharmaceuticals,undefined
[6] Inc.,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Conjunctival hyperemia; Glaucoma; Intraocular pressure; Netarsudil; Rho-associated protein kinase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1757 / 1775
页数：18
相关论文
共 50 条
  • [21] Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension
    Franks, Wendy
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (09) : 1643 - 1649
  • [22] Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension
    Shahid, Saima
    Rizvi, Syed Wajahat A.
    Khan, Adeeb A.
    Ashraf, Humayoun
    Akhter, Afeefa
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2024, 72 (03) : 427 - 431
  • [23] Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
    Wirta, David L.
    Kuwayama, Yasuaki
    Lu, Fenghe
    Shao, Hui
    Odani-Kawabata, Noriko
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 38 (03) : 240 - 251
  • [24] The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) as a primary therapy in patients with open-angle glaucoma or ocular hypertension
    Sall, K
    SURVEY OF OPHTHALMOLOGY, 2000, 44 : S155 - S162
  • [25] Survival of medical treatment success in primary open-angle glaucoma and ocular hypertension
    Fu, Dun Jack
    Ademisoye, Ebenezer
    Shih, Vanessa
    McNaught, Andrew Ian
    Khawaja, Anthony
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2024, 108 (12) : 1701 - 1707
  • [26] Noninvasive Detection of Mitochondrial Dysfunction in Ocular Hypertension and Primary Open-angle Glaucoma
    Geyman, Lawrence S.
    Suwan, Yanin
    Garg, Reena
    Field, Matthew G.
    Krawitz, Brian D.
    Mo, Shelley
    Pinhas, Alexander
    Ritch, Robert
    Rosen, Richard B.
    JOURNAL OF GLAUCOMA, 2018, 27 (07) : 592 - 599
  • [27] Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
    Fingeret, Murray
    Gaddie, Ian B.
    Bloomenstein, Marc
    CLINICAL AND EXPERIMENTAL OPTOMETRY, 2019, 102 (06) : 541 - 550
  • [28] Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical Trials
    Kawamura, Taichi
    Sato, Izumi
    Kawakami, Koji
    PLOS ONE, 2016, 11 (06):
  • [29] A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension
    Mrukwa-Kominek, Ewa
    Misiuk-Hojlo, Marta
    Csutak, Adrienne
    Stalmans, Ingeborg
    Garhofer, Gerhard
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (05) : 775 - 783
  • [30] Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
    Sanjay Asrani
    Jason Bacharach
    Edward Holland
    Hayley McKee
    Huan Sheng
    Richard A. Lewis
    Casey C. Kopczynski
    Theresa Heah
    Advances in Therapy, 2020, 37 : 1620 - 1631
12345